AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...
US FDA approves expanded use of Lilly's bowel disease drug Healthcare & Pharmaceuticalscategory· January 16, 2025 AbbVie plans to "commit less capital" towards experimental medicines for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback